ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Avastin Loses Indication for Breast Cancer

November 18, 2011

In Brief: James Cancer Hospial Recieves $20M Donation

January 22, 1999

Cooperative Groups Cut In On $1 Million Head 7 Neck Projects

March 25, 1977

Guest Editorial: Even Slam-Dunk Applications Can Benefit From Public Scrutiny and Discussion at ODAC

August 10, 2012

NCI Programs: Seven Win Awards For Cancer Genetics Network, Informatics

July 31, 1998

In Brief: Fred Hutchinson Center celebrates Massive Move Of 36 Labs, 400 Employees to New Campus

June 25, 1993